Nasdaq · CIK 0001267565
COLL COLLEGIUM PHARMACEUTICAL, INC
Insider trading from SEC Form 4. Last filing Jun 10, 2026. Close $22.09 on Oct 9, 2026, +1% from the 52-week low and -56% from the high.
COLLEGIUM PHARMACEUTICAL, INC (COLL) has 57 SEC Form 4 filings on file from 15 insiders, the latest filed on Jun 10, 2026. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
28 open-market trades have been scored at COLL. The newest: John Gordon Freund (director) sold $681 of stock on May 18, 2026, filed May 20, 2026, scored 30 (weak). The largest of the 28 shown: Shirley R. Kuhlmann (EVP and General Counsel) sold $2.4M on Mar 4, 2025, scored 50 (moderate). 3 insiders sold within 14 days of each other around May 18, 2026.
COLL closed at $22.09 on Oct 9, 2026, 1% above its 52-week low and 56% below its 52-week high.
25 Form 144 notices of planned sales are on file, the latest filed May 18, 2026.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
15
with a Form 4 at this company
Price and insider trades, last year
COLLOct 9, 2026 · close 22.09
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at COLLEGIUM PHARMACEUTICAL, INC, scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 30Weak | John Gordon Freund director sell | $681 20 shares | -0% | +17% from low-32% from high | |
| 26Weak | John Gordon Freund director sell | $143k 4,127 shares | -5% | +17% from low-32% from high | |
| 46Moderate | Nancy Lurker director sell | $162k 4,500 shares | -20% | +21% from low-30% from high | |
| 34Weak | Garen G Bohlin director sell | $323k 8,700 shares | -12% | +24% from low-28% from high | |
| 18Weak | David Dieter EVP & General Counsel sell | $488k 13,976 shares | -15% | +41% from low-30% from high | |
| 16Weak | David Dieter EVP & General Counsel sell | $228k 6,224 shares | -6% | +51% from low-25% from high | |
| 38Weak | Scott Dreyer EVP & Chief Commercial Officer sell | $2.0M 49,976 shares | -41% | +62% from low-20% from high | |
| 16Weak | Scott Dreyer EVP & Chief Commercial Officer sell | $848k 17,600 shares | -15% | +94% from low0% from high | |
| 34Weak | Rita J. Balice-Gordon director sell | $172k 3,650 shares | -6% | +94% from low0% from high | |
| 43Moderate | John A. Fallon director sell | $1.6M 34,853 shares | -35% | +92% from low0% from high | |
| 40Moderate | Colleen Tupper EVP & Chief Financial Officer sell | $1.2M 30,000 shares | -19% | +65% from low0% from high | |
| 55Moderate | Thomas B Smith EVP and Chief Medical Officer sell | $672k 17,478 shares | -20% | +57% from low-7% from high | |
| 20Weak | Scott Dreyer EVP & Chief Commercial Officer sell | $626k 16,389 shares | -14% | +55% from low-9% from high | |
| 27Weak | Gino Santini director sell | $201k 5,405 shares | -5% | +53% from low-10% from high | |
| 51Moderate | Rubric Capital Management LP owner sell | $946k 25,000 shares | -1% | +53% from low-10% from high | |
| 7Weak | Scott Dreyer EVP & Chief Commercial Officer sell | $185k 4,861 shares | -4% | +53% from low-10% from high | |
| 56Moderate | John Gordon Freund director sell | $401k 11,659 shares | -34% | +42% from low-17% from high | |
| 12Weak | John Gordon Freund director sell | $202k 6,601 shares | -9% | +23% from low-27% from high | |
| 28Weak | Scott Dreyer EVP & Chief Commercial Officer sell | $625k 20,808 shares | -17% | - | |
| 23Weak | Colleen Tupper EVP & Chief Financial Officer sell | $228k 7,602 shares | -5% | - | |
| 18Weak | Scott Dreyer EVP & Chief Commercial Officer sell | $68k 2,255 shares | -2% | - | |
| 22Weak | Colleen Tupper EVP & Chief Financial Officer sell | $29k 977 shares | -1% | - | |
| 31Weak | Colleen Tupper EVP & Chief Financial Officer sell | $313k 10,445 shares | -6% | - | |
| 32Weak | Scott Dreyer EVP & Chief Commercial Officer sell | $462k 15,387 shares | -11% | - | |
| 21Weak | Scott Dreyer EVP & Chief Commercial Officer sell | $169k 5,643 shares | -4% | - | |
| 27Weak | Colleen Tupper EVP & Chief Financial Officer sell | $104k 3,453 shares | -2% | - | |
| 50Moderate | Shirley R. Kuhlmann EVP and General Counsel sell | $2.4M 86,067 shares | -44% | - | |
| 9Weak | Shirley R. Kuhlmann EVP and General Counsel sell | $909k 27,500 shares | -19% | - |
Planned sales
Form 144 notices filed before a sale of restricted or control stock, newest first. The sale itself usually reaches a Form 4 within days. All planned sales
| Filed | Seller | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| May 18, 2026 | Freund John Gordon Director | 30 0.00% of outstanding | $1,022 | May 18, 2026 | $143k |
| May 15, 2026 | Freund John Gordon Director | 4,127 0.01% of outstanding | $143k | May 15, 2026 | none |
| May 13, 2026 | Lurker Nancy Director | 4,500 0.01% of outstanding | $162k | May 13, 2026 | none |
| May 11, 2026 | BOHLIN GAREN G Director | 8,700 0.03% of outstanding | $323k | May 11, 2026 | none |
| Mar 18, 2026 | Dieter David Officer | 13,976 0.04% of outstanding | $488k | Mar 18, 2026 | $228k |
| Mar 9, 2026 | Dieter David Officer | 6,224 0.02% of outstanding | $228k | Mar 9, 2026 | none |
| Mar 3, 2026 | Dreyer Scott Officer | 49,976 0.16% of outstanding | $2.0M | Mar 3, 2026 | $848k |
| Dec 17, 2025 | RITA BALICE-GORDON DIRECTOR | 3,650 0.01% of outstanding | $172k | Dec 5, 2025 | none |
| Dec 8, 2025 | Dreyer Scott Officer | 17,600 0.06% of outstanding | $848k | Dec 8, 2025 | none |
| Nov 12, 2025 | Fallon John A. Director | 34,853 0.11% of outstanding | $1.6M | Nov 12, 2025 | none |
| Nov 6, 2025 | Tupper Colleen Officer | 30,000 0.09% of outstanding | $1.2M | Nov 6, 2025 | none |
| Aug 29, 2025 | Smith Thomas B Officer | 17,478 0.06% of outstanding | $672k | Aug 29, 2025 | none |
| Aug 18, 2025 | Dreyer Scott Officer | 16,389 0.05% of outstanding | $626k | Aug 18, 2025 | $185k |
| Aug 15, 2025 | SANTINI GINO Director | 5,405 0.02% of outstanding | $201k | Aug 15, 2025 | none |
| Aug 13, 2025 | Dreyer Scott Officer | 4,861 0.02% of outstanding | $185k | Aug 13, 2025 | none |
| Jul 9, 2025 | Heffernan Michael Thomas Former Director | 10,328 0.03% of outstanding | $332k | Jul 9, 2025 | $1.2M |
| Jul 8, 2025 | Heffernan Michael Thomas Former Director | 790 0.00% of outstanding | $25k | Jul 8, 2025 | $1.2M |
| Jul 7, 2025 | Heffernan Michael Thomas Former Director | 14,210 0.04% of outstanding | $444k | Jul 7, 2025 | $757k |
| Jul 2, 2025 | Melincoff Gwen A Former Director | 47,082 0.15% of outstanding | $1.4M | Jul 2, 2025 | none |
| Jul 2, 2025 | Heffernan Michael Thomas Former Director | 25,000 0.08% of outstanding | $757k | Jul 2, 2025 | none |
| Jun 9, 2025 | Freund John Gordon Director | 6,601 0.02% of outstanding | $202k | Jun 9, 2025 | none |
| Mar 21, 2025 | Dreyer Scott Officer | 18,881 0.06% of outstanding | $567k | Mar 21, 2025 | $756k |
| Mar 21, 2025 | Tupper Colleen Officer | 6,396 0.02% of outstanding | $192k | Mar 21, 2025 | $482k |
| Mar 20, 2025 | Dreyer Scott Officer | 1,927 0.01% of outstanding | $58k | Mar 20, 2025 | $699k |
| Mar 20, 2025 | Kuhlmann Shirley R. Former Officer | 40,494 0.13% of outstanding | $1.2M | Mar 20, 2025 | $3.3M |
Transactions
The newest 50 of 117 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 8, 2026 | Gino Santini director | MOption exercise Common Stock | +8,700 | $16.49 | $143k | 112,483 | Jun 10, 2026 |
| Jun 8, 2026 | Gino Santini director | MOption exercise Stock Option (Right to Purchase)derivative | -8,700 | $0.00 | $0 | 0 | Jun 10, 2026 |
| May 18, 2026 | John Gordon Freund director | SOpen-market sale Common Stock | -20 | $34.05 | $681 | 83,952 | May 20, 2026 |
| May 14, 2026 | Garen G Bohlin director | AGrant or award Common Stock | +8,741 | $0.00 | $0 | 71,000 | May 18, 2026 |
| May 14, 2026 | Gino Santini director | AGrant or award Common Stock | +8,741 | $0.00 | $0 | 103,783 | May 18, 2026 |
| May 14, 2026 | John Gordon Freund director | AGrant or award Common Stock | +8,741 | $0.00 | $0 | 79,399 | May 18, 2026 |
| May 14, 2026 | Nancy Lurker director | AGrant or award Common Stock | +8,741 | $0.00 | $0 | 26,758 | May 18, 2026 |
| May 14, 2026 | Donovan Michael Glancy director | AGrant or award Common Stock | +17,482 | $0.00 | $0 | 17,482 | May 18, 2026 |
| May 14, 2026 | Carlos Paya V director | AGrant or award Common Stock | +8,741 | $0.00 | $0 | 28,323 | May 18, 2026 |
| May 14, 2026 | Rita J. Balice-Gordon director | AGrant or award Common Stock | +8,741 | $0.00 | $0 | 61,370 | May 18, 2026 |
| May 15, 2026 | John Gordon Freund director | MOption exercise Common Stock | +8,700 | $16.49 | $143k | 88,099 | May 18, 2026 |
| May 15, 2026 | John Gordon Freund director | SOpen-market sale Common Stock | -4,127 | $34.54 | $143k | 83,972 | May 18, 2026 |
| May 15, 2026 | John Gordon Freund director | MOption exercise Stock Option (Right to Purchase)derivative | -8,700 | $0.00 | $0 | 0 | May 18, 2026 |
| May 13, 2026 | Nancy Lurker director | SOpen-market sale Common Stock | -4,500 | $35.97 | $162k | 18,017 | May 15, 2026 |
| May 11, 2026 | Garen G Bohlin director | MOption exercise Common Stock | +8,700 | $16.49 | $143k | 70,959 | May 13, 2026 |
| May 11, 2026 | Garen G Bohlin director | SOpen-market sale Common Stock | -8,700 | $37.18 | $323k | 62,259 | May 13, 2026 |
| May 11, 2026 | Garen G Bohlin director | MOption exercise Stock Option (Right to Purchase)derivative | -8,700 | $0.00 | $0 | 0 | May 13, 2026 |
| Mar 17, 2026 | David Dieter EVP & General Counsel | FTax withholding Common Stock | -8,840 | $35.72 | $316k | 68,231 | Apr 3, 2026 |
| Mar 18, 2026 | David Dieter EVP & General Counsel | SOpen-market sale Common Stock10b5-1 | -13,976 | $34.92 | $488k | 77,071 | Mar 20, 2026 |
| Mar 9, 2026 | David Dieter EVP & General Counsel | SOpen-market sale Common Stock10b5-1 | -6,224 | $36.65 | $228k | 91,047 | Mar 11, 2026 |
| Mar 3, 2026 | Scott Dreyer EVP & Chief Commercial Officer | SOpen-market sale Common Stock10b5-1 | -46,417 | $40.36 | $1.9M | 75,329 | Mar 5, 2026 |
| Mar 3, 2026 | Scott Dreyer EVP & Chief Commercial Officer | SOpen-market sale Common Stock10b5-1 | -3,559 | $40.99 | $146k | 71,770 | Mar 5, 2026 |
| Feb 10, 2026 | Colleen Tupper EVP & Chief Financial Officer | AGrant or award Common Stock | +26,421 | $0.00 | $0 | 153,088 | Feb 12, 2026 |
| Feb 10, 2026 | David Dieter EVP & General Counsel | AGrant or award Common Stock | +22,194 | $0.00 | $0 | 91,047 | Feb 12, 2026 |
| Feb 10, 2026 | Vikram Karnani President and CEO | AGrant or award Common Stock | +79,264 | $0.00 | $0 | 176,629 | Feb 12, 2026 |
| Feb 10, 2026 | Scott Dreyer EVP & Chief Commercial Officer | AGrant or award Common Stock | +19,023 | $0.00 | $0 | 122,636 | Feb 12, 2026 |
| Feb 10, 2026 | Thomas B Smith EVP and Chief Medical Officer | AGrant or award Common Stock | +14,268 | $0.00 | $0 | 85,312 | Feb 12, 2026 |
| Feb 10, 2026 | Colleen Tupper EVP & Chief Financial Officer | AGrant or award Common Stock | +32,734 | $0.00 | $0 | 185,822 | Feb 12, 2026 |
| Feb 10, 2026 | David Dieter EVP & General Counsel | AGrant or award Common Stock | +9,005 | $0.00 | $0 | 100,052 | Feb 12, 2026 |
| Feb 10, 2026 | Vikram Karnani President and CEO | AGrant or award Common Stock | +32,531 | $0.00 | $0 | 209,160 | Feb 12, 2026 |
| Feb 10, 2026 | Scott Dreyer EVP & Chief Commercial Officer | AGrant or award Common Stock | +30,702 | $0.00 | $0 | 153,338 | Feb 12, 2026 |
| Feb 10, 2026 | Thomas B Smith EVP and Chief Medical Officer | AGrant or award Common Stock | +22,774 | $0.00 | $0 | 108,086 | Feb 12, 2026 |
| Feb 10, 2026 | Thomas B Smith EVP and Chief Medical Officer | FTax withholding Common Stock | -5,897 | $46.75 | $276k | 102,189 | Feb 12, 2026 |
| Feb 10, 2026 | Colleen Tupper EVP & Chief Financial Officer | FTax withholding Common Stock | -11,861 | $46.75 | $555k | 173,961 | Feb 12, 2026 |
| Feb 10, 2026 | David Dieter EVP & General Counsel | FTax withholding Common Stock | -2,781 | $46.75 | $130k | 97,271 | Feb 12, 2026 |
| Feb 10, 2026 | Vikram Karnani President and CEO | FTax withholding Common Stock | -11,296 | $46.75 | $528k | 197,864 | Feb 12, 2026 |
| Feb 10, 2026 | Scott Dreyer EVP & Chief Commercial Officer | FTax withholding Common Stock | -9,977 | $46.75 | $466k | 143,361 | Feb 12, 2026 |
| Feb 10, 2026 | Thomas B Smith EVP and Chief Medical Officer | FTax withholding Common Stock | -11,538 | $46.75 | $539k | 90,651 | Feb 12, 2026 |
| Feb 10, 2026 | Colleen Tupper EVP & Chief Financial Officer | FTax withholding Common Stock | -26,679 | $46.75 | $1.2M | 147,282 | Feb 12, 2026 |
| Feb 10, 2026 | Scott Dreyer EVP & Chief Commercial Officer | FTax withholding Common Stock | -21,615 | $46.75 | $1.0M | 121,746 | Feb 12, 2026 |
| Dec 8, 2025 | Scott Dreyer EVP & Chief Commercial Officer | MOption exercise Common Stock10b5-1 | +17,600 | $15.90 | $280k | 121,213 | Dec 10, 2025 |
| Dec 8, 2025 | Scott Dreyer EVP & Chief Commercial Officer | SOpen-market sale Common Stock10b5-1 | -11,125 | $47.89 | $533k | 110,088 | Dec 10, 2025 |
| Dec 8, 2025 | Scott Dreyer EVP & Chief Commercial Officer | SOpen-market sale Common Stock10b5-1 | -6,475 | $48.66 | $315k | 103,613 | Dec 10, 2025 |
| Dec 8, 2025 | Scott Dreyer EVP & Chief Commercial Officer | MOption exercise Stock Option (Right to Purchase)derivative10b5-1 | -17,600 | $0.00 | $0 | 0 | Dec 10, 2025 |
| Dec 5, 2025 | Rita J. Balice-Gordon director | SOpen-market sale Common Stock | -3,650 | $47.03 | $172k | 52,629 | Dec 9, 2025 |
| Nov 12, 2025 | John A. Fallon director | MOption exercise Common Stock | +15,000 | $16.49 | $247k | 79,634 | Nov 14, 2025 |
| Nov 12, 2025 | Vikram Karnani President and CEO | FTax withholding Common Stock | -8,983 | $47.35 | $425k | 96,989 | Nov 14, 2025 |
| Nov 12, 2025 | John A. Fallon director | MOption exercise Common Stock | +19,853 | $9.33 | $185k | 99,487 | Nov 14, 2025 |
| Nov 12, 2025 | John A. Fallon director | SOpen-market sale Common Stock | -34,853 | $47.21 | $1.6M | 64,634 | Nov 14, 2025 |
| Nov 12, 2025 | John A. Fallon director | MOption exercise Stock Option (Right to Purchase)derivative | -15,000 | $0.00 | $0 | 0 | Nov 14, 2025 |
50 of 117 rows shown.
Insiders
Everyone who has filed a Form 4 here.
- Garen G Bohlindirector
- Rita J. Balice-Gordondirector
- David DieterEVP & General Counsel
- Scott DreyerEVP & Chief Commercial Officer
- John A. Fallondirector
- John Gordon Freunddirector
- Donovan Michael Glancydirector
- Vikram KarnaniPresident and CEO
- Shirley R. KuhlmannEVP and General Counsel
- Nancy Lurkerdirector
- Carlos Paya Vdirector
- Rubric Capital Management LPowner
- Gino Santinidirector
- Thomas B SmithEVP and Chief Medical Officer
- Colleen TupperEVP & Chief Financial Officer
Questions about COLL
Answered from the filings on this page, as of the latest one.
Are insiders buying COLL?
No. In the last 90 days no insider at COLLEGIUM PHARMACEUTICAL, INC bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade COLL on the open market?
John Gordon Freund (director) sold $681 of COLL on May 18, 2026 and filed the Form 4 on May 20, 2026. InsiderTell scored 30 (weak), with 3 insiders on the same side within 14 days.
How many insiders file Form 4 at COLLEGIUM PHARMACEUTICAL, INC?
15 people have filed a Form 4 at COLLEGIUM PHARMACEUTICAL, INC, among them Garen G Bohlin (director), Rita J. Balice-Gordon (director), David Dieter (EVP & General Counsel). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.